ProQR Therapeutics NV Additional Sepofarsen Analyses and Company Strategy Update Call Transcript
Thank you, operator, and good day, everyone. I'm Sarah Kiely, Vice President of Investor Relations and Corporate Communications at ProQR.
Today, we issued a press release announcing findings from additional analyses from the Phase II/III Illuminate trial of sepofarsen and an update on our corporate strategy. This press release can be found on our website at www.proqr.com.
With me today from the management team is Daniel de Boer, our Founder and CEO. Following his prepared remarks, we will have a Q&A session, which will include Daniel, along with Dr. Aniz Girach, our Chief Medical Officer; Gerard Platenburg, our Co-Founder and Chief Innovation Officer; and Smital Shah, our Chief Business and Financial Officer. (Operator Instructions)
During the call today, we will make forward-looking statements. There are risks and uncertainties associated with an investment in ProQR, which are described in detail in our SEC filings.
I
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |